Elicio Therapeutics Inc. (ELTX)vsJohnson & Johnson (JNJ)
ELTX
Elicio Therapeutics Inc.
$1.56
-4.29%
HEALTHCARE · Cap: $43.08M
JNJ
Johnson & Johnson
$283.62
+1.11%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
ELTX
Avoid17
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ELTX
ELTX has a balanced fundamental profile.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : ELTX
The primary concerns for ELTX are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.78 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
ELTX profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
ELTX carries more volatility with a beta of 2.00 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 17/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elicio Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002, leverages a proprietary Amphiphilic TLR9 Agonist to elicit robust immune responses against various cancer types, aiming to enhance patient outcomes. By concentrating on personalized cancer vaccines and groundbreaking immunotherapeutic approaches, Elicio Therapeutics is uniquely positioned to tackle significant unmet clinical needs in oncology, while advancing its compelling pipeline through rigorous clinical trials that could redefine the standard of cancer care.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?